Table 2

Demographic characteristics and serum NFL levels of disease controls

DiagnosisnM/FAgeSerum NFL (pg/mL)
Axonal polyneuropathy77/071 (57–83)42.2 (1.1–114)
Hereditary spastic paraparesis (HSP)43/147 (21–56)30.3 (12.4–41.2)
Inclusion body myopathy (IBM)42/266 (46–77)48.9 (27.4–71.4)
Chronic inflammatory demyelinating polyneuropathy (CIDP)32/181 (75–82)135 (132–155)
Peroneal nerve lesion32/148 (48–69)11.4 (9.3–90.1)
Benign fasciculations22/044 (38–50)17.2 (16.4–18)
Unspecified myopathy22/065 (44–86)10.9 (0.7–21.2)
Somatoform disorder21/152 (46–58)16.3 (14.3–18.4)
Subjective weakness without evidence of neurological disease21/144 (39–49)9.5 (6.1–12.9)
Spinocerebellar ataxia (SCA)10/17227.3
Pseudobulbar and cerebellar syndrome without evidence of MND11/07181.6
Anterior spinal artery syndrome10/14936
Transverse myelitis10/14790.4
Polyradiculomyelitis11/06136.5
Neuralgic amyotrophy11/06322
Spondylosis with lumbar radiculopathies11/07447.9
Bilateral L5 radiculitis11/06620.1
Mononeuritis multiplex11/07926.8
Autoimmune polyneuropathy and myopathy11/07246.9
Limb-girdle muscular dystrophy (LGMD)11/024210
Myositis10/17016.1
Myalgia-cramp-fasciculation syndrome11/05614
Lower limb weakness without evidence of MND11/04316.8
Lingual atrophy without evidence of MND10/14317
  • For age and NFL levels, when the group includes more than one patient, median values are given, with ranges in brackets; when there is only one patient, his/her serum NFL level is indicated. MND, motor neuron disease; NFL, neurofilament light chain.